肝内胆管细胞癌的治疗进展

国际肿瘤学杂志››2016,Vol. 43››Issue (1): 60-63.doi:10.3760/cma.j.issn.1673,422X.2016.01.017

罗梦超,丁超峰,吴健,郑树森

310003杭州，浙江大学医学院附属第一医院肝胆外科卫生部多器官联合移植研究重点实验室感染性疾病诊治协同创新中心

收稿日期:2015-08-02出版日期:2016-01-08发布日期:2015-12-03
通讯作者:郑树森 E-mail:shusenzheng@zju.edu.cn
基金资助:

国家高技术研究发展计划（2012AA021002）；国家卫生和计划生育委员会公益性行业科研专项（201302009）；浙江省自然科学基金（LQ15H160002）

Treatment progress of intrahepatic cholangiocarcinoma

Luo Mengchao, Ding Chaofeng, Wu Jian, Zheng Shusen

Department of Hepatobiliary Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University; Key Laboratory of Combined Multiorgan Transplantation, Ministry of Public Health; Collaborative Innovation Center of Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China

Received:2015-08-02Online:2016-01-08Published:2015-12-03
Contact:Zheng Shusen E-mail:shusenzheng@zju.edu.cn
Supported by:

National High Technology Research and Development Program of China (863 Program) (2012AA021002); Special Fund for Health Research in the Public Welfare of National Health and Family Planning Commission of China (201302009); Natural Science Foundation of Zhejiang Province of China (LQ15H160002)

摘要/Abstract

摘要：肝内胆管细胞癌（ICC）当前首选治疗手段仍为手术治疗。吉西他滨联合顺铂全身化疗方案可推荐为不可切除ICC患者的标准治疗方案。近年来新辅助治疗联合肝移植方案的提出为肝移植治疗ICC开拓了新的治疗前景。此外，放疗、介入治疗、射频消融治疗、分子靶向治疗等也是综合治疗ICC的重要组成部分。

罗梦超,丁超峰,吴健,郑树森. 肝内胆管细胞癌的治疗进展[J]. 国际肿瘤学杂志, 2016, 43(1): 60-63.

Luo Mengchao, Ding Chaofeng, Wu Jian, Zheng Shusen. Treatment progress of intrahepatic cholangiocarcinoma[J]. Journal of International Oncology, 2016, 43(1): 60-63.

［1］ Charbel H, AlKawas FH. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis［J］. CurrGastroenterol Rep, 2011, 13(2): 182-187. DOI:10.1007/s1189401101788. ［2］ Lubezky N, Facciuto M, Harimoto N, et al. Surgical treatment of intrahepatic cholangiocarcinoma in the USA［J］. J Hepatobiliary Pancreat Sci, 2015, 22(2): 124-130. DOI:10.1002/jhbp.157. ［3］ Bergeat D, Sulpice L, Rayar M, et al. Extended liver resections for intrahepatic cholangiocarcinoma: friend or foe?［J］. Surgery, 2015, 157(4): 656-665. DOI:10.1016/j.surg.2014.11.011. ［4］ De Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multiinstitutional analysis of prognostic factors and lymph node assessment［J］. J Clin Oncol, 2011, 29(23): 3140-3145. DOI:10.1200/JCO.2011.35.6519. ［5］ Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma［J］. J Hepatol, 2014, 60(6): 1268-1289. DOI:10.1016/j.jhep.2014.01.021. ［6］ Sapisochin G, Rodríguez De Lope C, Gastaca M, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?［J］. Am J Transplant, 2014, 14(3): 660-667. DOI:10.1111/ajt.12591. ［7］ Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24year experience in a single center［J］. Arch Surg, 2011, 146(6): 683-689. DOI:10.1001/archsurg.2011.116. ［8］ Rana A, Hong JC. Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma［J］. Curr Opin Gastroenterol, 2012, 28(3): 258265. DOI:10.1097/MOG.0b013e32835168db. ［9］ Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours:amulticentrerandomised phase Ⅱ study—the UK ABC01 study［J］. Br J Cancer, 2009, 101(4): 621-627. DOI: 10.1038/sj.bjc.6605211. ［10］ Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer［J］. N Engl J Med, 2010, 362(14): 1273-1281. DOI:10.1056/NEJMoa0908721. ［11］ Fisher SB, Patel SH, Kooby DA, et al. Lymphovascular and perineuralinvasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multiinstitution analysis［J］. HPB (Oxford), 2012, 14(8): 514-522. DOI:10.1111/j.14772574.2012.00489.x. ［12］ Barney BM, Olivier KR, Miller RC, et al. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma［J］. Radiat Oncol, 2012, 7: 67. DOI:10.1186/1748-717X-7-67. ［13］ Jiang W, Zeng ZC, Tang ZY, et al. Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases［J］. J Cancer Res Clin Oncol, 2010, 136(9): 13231331. DOI:10.1007/s00432-010-0783-1. ［14］ Giorgio A, Calisti G, De Stefano G, et al. Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centreexperience［J］. Anticancer Res, 2011, 31(12): 4575-4580. ［15］ Kim JH, Won HJ, Shin YM, et al. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection［J］. Eur J Radiol, 2011, 80(3): e221-e225. DOI:10.1016/j.ejrad.2010.09.019. ［16］ Vogl TJ, Naguib NN, NourEldin NE, et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success［J］. Int J Cancer, 2012, 131(3): 733-740. DOI:10.1002/ijc.26407. ［17］ Shen WF, Zhong W, Liu Q, et al. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study［J］. World J Surg, 2011, 35(9): 20832091. DOI:10.1007/s00268-011-1171-y. ［18］ Kuhlmann JB, Euringer W, Spangenberg HC, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting beadtransarterial chemoembolization and systemic chemotherapy［J］. Eur J Gastroenterol Hepatol, 2012, 24(4): 437443. DOI:10.1097/MEG.0b013e3283502241. ［19］ AlAdra DP, Gill RS, Axford SJ, et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium90 radioembolization: a systematic review and pooled analysis［J］. Eur J Surg Oncol, 2015, 41(1): 120127. DOI:10.1016/j.ejso.2014.09.007. ［20］ Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study［J］. Lancet Oncol, 2010, 11(12): 1142-1148. DOI:10.1016/S1470-2045(10)70247-3. ［21］ Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliarytract cancer: a multicentre, openlabel, randomised, phase 3 study［J］. Lancet Oncol, 2012, 13(2): 181-188. DOI:10.1016/S1470-2045(11)70301-1.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[6]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[7]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[8]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[9]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[10]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[11]	彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[12]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[13]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[14]	黄镇, 陈永顺.循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[15]	黄辉, 丁江华.靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.